PE20231643A1 - Receptor de antigeno quimerico combinado dirigido a cd19 y cd20 y aplicaciones de los mismos - Google Patents

Receptor de antigeno quimerico combinado dirigido a cd19 y cd20 y aplicaciones de los mismos

Info

Publication number
PE20231643A1
PE20231643A1 PE2022002042A PE2022002042A PE20231643A1 PE 20231643 A1 PE20231643 A1 PE 20231643A1 PE 2022002042 A PE2022002042 A PE 2022002042A PE 2022002042 A PE2022002042 A PE 2022002042A PE 20231643 A1 PE20231643 A1 PE 20231643A1
Authority
PE
Peru
Prior art keywords
seq
region
chimeric antigen
cell
antigen receptor
Prior art date
Application number
PE2022002042A
Other languages
English (en)
Inventor
Yihong Yao
Jiaqi Huang
Xin Yao
Shigui Zhu
Yanfeng Li
Yutian Wei
Original Assignee
Cellular Biomedicine Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Biomedicine Group Inc filed Critical Cellular Biomedicine Group Inc
Publication of PE20231643A1 publication Critical patent/PE20231643A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464424—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Refiere a un receptor de antigeno quimerico biespecifico (CAR) dirigido a CD19 y CD20. La region a antigeno anti-CD20, presenta una region variable de cadena ligera (VL1) y de cadena pesada (VH1), cuyas secuencias de aminoacidos son un 80%-100% identicas a las de SEQ ID NO: 4 y SEQ ID NO: 3. Asimismo, en cuanto a la region a antigeno anti-CD19, la region variable de cadena ligera (VL2) y de cadena pesada (VH2), tienen secuencias con un 80%-100% de identidad a las de SEQ ID NO: 5 y SEQ ID NO: 6. Adicionalmente, dicho receptor presenta un peptido senal, cuya secuencia es 80%-100% identica a la de SEQ ID NO. 16; una region bisagra de Ig4, CD8, CD28 o CD137; un dominio de transmembrana de CD8 o CD3?; una region coestimuladora de 4-1BB (CD137) o LFA-1 (CD11a/CD18) y un dominio de senalizacion citoplasmatica de CD3?. Tambien, refieren a una celula NK o celula T que expresan el CAR biespecifico; un acido nucleico que lo codifica, vectores que lo comprenden y metodos para tratar el linfoma de celulas B CD19 y/o CD20 positivas, leucemia y/o mieloma multiple, y otras enfermedades.
PE2022002042A 2020-03-17 2021-03-17 Receptor de antigeno quimerico combinado dirigido a cd19 y cd20 y aplicaciones de los mismos PE20231643A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010188038.1A CN113402612A (zh) 2020-03-17 2020-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用
US16/877,069 US11207349B2 (en) 2020-03-17 2020-05-18 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
PCT/CN2020/109645 WO2021184673A1 (en) 2020-03-17 2020-08-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
US202163154032P 2021-02-26 2021-02-26
PCT/US2021/022779 WO2021188681A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof

Publications (1)

Publication Number Publication Date
PE20231643A1 true PE20231643A1 (es) 2023-10-16

Family

ID=77677447

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002042A PE20231643A1 (es) 2020-03-17 2021-03-17 Receptor de antigeno quimerico combinado dirigido a cd19 y cd20 y aplicaciones de los mismos

Country Status (18)

Country Link
US (5) US11207349B2 (es)
EP (1) EP3989986A4 (es)
JP (3) JP2023518134A (es)
KR (2) KR102520550B1 (es)
CN (2) CN113402612A (es)
AU (2) AU2021238330B2 (es)
BR (1) BR112022018677A2 (es)
CA (2) CA3169235A1 (es)
CL (1) CL2022002522A1 (es)
CO (1) CO2022014259A2 (es)
CR (1) CR20220507A (es)
DO (1) DOP2022000195A (es)
EC (1) ECSP22079948A (es)
IL (1) IL296473A (es)
MX (1) MX2022011554A (es)
NZ (1) NZ793365A (es)
PE (1) PE20231643A1 (es)
WO (2) WO2021184673A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2023208157A1 (zh) * 2022-04-29 2023-11-02 上海先博生物科技有限公司 靶向cd19的嵌合抗原受体及其应用
CN114990069B (zh) * 2022-05-17 2023-09-22 郑州大学第一附属医院 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用
WO2024044743A1 (en) * 2022-08-26 2024-02-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
CN118146393A (zh) * 2022-11-07 2024-06-07 武汉波睿达生物科技有限公司 一种信号肽序列优化的靶向cd19的嵌合抗原受体及其应用
US20240285762A1 (en) 2023-02-28 2024-08-29 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2008121420A1 (en) 2007-03-30 2008-10-09 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
KR102243575B1 (ko) 2010-12-09 2021-04-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
ES2774160T3 (es) 2012-02-13 2020-07-17 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
CN104718284A (zh) 2012-05-25 2015-06-17 塞勒克提斯公司 工程化用于免疫疗法的异体和免疫抑制耐受性t细胞的方法
RS61345B1 (sr) 2012-08-20 2021-02-26 Hutchinson Fred Cancer Res Postupak i kompozicije za ćelijsku imunoterapiju
KR20230022452A (ko) 2013-02-15 2023-02-15 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
ES2837856T3 (es) * 2013-12-20 2021-07-01 Hutchinson Fred Cancer Res Moléculas efectoras quiméricas etiquetadas y receptores de las mismas
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
NZ764530A (en) 2014-06-02 2024-07-05 The Us Secretary Department Of Health And Human Services Chimeric antigen receptors targeting cd-19
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
CN117427091A (zh) 2014-10-20 2024-01-23 朱诺治疗学股份有限公司 用于过继细胞治疗中的给药的组合物和方法
CA3008162A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
UA120286C2 (uk) 2015-01-08 2019-11-11 Ґенмаб А/С Біспецифічне антитіло проти cd3 і cd20
EP3259352A4 (en) 2015-02-19 2018-12-05 University of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
US11091546B2 (en) * 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
EP3288569A4 (en) * 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2016179319A1 (en) 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
EP4286511A3 (en) 2015-06-12 2024-03-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
US10493139B2 (en) * 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
CN108026534B (zh) 2015-08-05 2021-08-31 赛莱博迈德公司 嵌合抗原受体和其中表达有嵌合抗原受体的t细胞
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US11890301B2 (en) 2015-08-28 2024-02-06 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
WO2017173403A1 (en) * 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
EP3984559A1 (en) 2016-04-01 2022-04-20 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
TW202340473A (zh) * 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
CN108276493B (zh) 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN110691610A (zh) * 2017-02-22 2020-01-14 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
US11434290B2 (en) 2017-06-08 2022-09-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced NFκB signaling
AU2018309735A1 (en) 2017-07-31 2020-02-20 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
CN109423495A (zh) 2017-08-24 2019-03-05 上海恒润达生生物科技有限公司 一种双靶向嵌合抗原受体及其用途
WO2019055842A1 (en) 2017-09-15 2019-03-21 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD19 IMMUNOTHERAPY
TW201922256A (zh) * 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
MA51428A (fr) 2017-12-22 2020-11-04 Bluebird Bio Inc Récepteur d'antigène chimérique multivalent
CN108315305B (zh) 2017-12-26 2020-11-06 沣潮医药科技（上海）有限公司 携带嵌合抗原受体的免疫细胞外泌体的制备方法及其应用
CN108017717B (zh) 2018-01-24 2019-08-16 首都医科大学宣武医院 一种用于体外高效定向扩增的嵌合抗原受体及其应用
US20230183313A1 (en) 2018-02-11 2023-06-15 Jiangsu Hengrui Medicine Co., Ltd. Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
JP7467414B2 (ja) 2018-04-28 2024-04-15 北京永泰瑞科生物科技有限公司 改良したｔ細胞治療方法
CN110526983B (zh) 2018-05-24 2022-02-11 北京马力喏生物科技有限公司 改良型抗cd19 car-t细胞
CN110606893B (zh) 2018-06-15 2022-11-15 北昊干细胞与再生医学研究院有限公司 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
CA3115139A1 (en) 2018-10-01 2020-04-09 Adicet Bio Inc. Compositions and methods regarding engineered and non-engineered .gamma..delta.-t cells for treatment of hematological tumors
CN109536455B (zh) 2018-12-11 2020-02-21 武汉波睿达生物科技有限公司 一种car-nk细胞及其制备方法和应用
JP7386382B2 (ja) * 2018-12-12 2023-11-27 カイト ファーマ インコーポレイテッド キメラ抗原受容体及びｔ細胞受容体並びに使用方法
CN109575143B (zh) 2018-12-29 2022-06-17 博生吉医药科技(苏州)有限公司 双特异性cd20-cd19-car及其应用
WO2020151752A1 (zh) 2019-01-22 2020-07-30 亘喜生物科技（上海）有限公司 Cd20组合靶向的工程化免疫细胞
CN112390891B (zh) 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 嵌合抗原受体及其构建方法和应用
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN112608387B (zh) 2020-12-21 2023-05-05 汤朝阳 Cd19和cd20双靶点嵌合抗原受体及其应用

Also Published As

Publication number Publication date
WO2021184673A1 (en) 2021-09-23
NZ793365A (en) 2023-03-31
MX2022011554A (es) 2022-12-13
EP3989986A1 (en) 2022-05-04
AU2021238330A1 (en) 2022-11-17
US20220249568A1 (en) 2022-08-11
IL296473A (en) 2022-11-01
ECSP22079948A (es) 2022-12-30
BR112022018677A2 (pt) 2023-02-23
KR20220145411A (ko) 2022-10-28
JP7212222B2 (ja) 2023-01-25
KR102520550B1 (ko) 2023-04-12
CO2022014259A2 (es) 2022-10-31
CN115955974A (zh) 2023-04-11
EP3989986A4 (en) 2022-10-12
AU2021238330B2 (en) 2023-02-23
CR20220507A (es) 2022-11-22
JP2023518134A (ja) 2023-04-28
US11633430B2 (en) 2023-04-25
AU2023200268A1 (en) 2023-02-16
US20210290673A1 (en) 2021-09-23
WO2021188681A1 (en) 2021-09-23
CA3169239A1 (en) 2021-09-23
DOP2022000195A (es) 2023-02-28
US11439665B2 (en) 2022-09-13
CL2022002522A1 (es) 2023-04-21
US20220288123A1 (en) 2022-09-15
CN113402612A (zh) 2021-09-17
KR20230053705A (ko) 2023-04-21
US20220031752A1 (en) 2022-02-03
US20240139243A1 (en) 2024-05-02
JP2022536195A (ja) 2022-08-12
CA3169235A1 (en) 2021-09-23
US11207349B2 (en) 2021-12-28
JP2023027314A (ja) 2023-03-01

Similar Documents

Publication Publication Date Title
PE20231643A1 (es) Receptor de antigeno quimerico combinado dirigido a cd19 y cd20 y aplicaciones de los mismos
HRP20201906T1 (hr) Označene kimerne efektorske molekule i njihovi receptori
FI3896091T3 (fi) BCMA:han kohdentuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
JP2020517295A5 (es)
RU2018109426A (ru) Химерные антигенные рецепторы со встроенными контролируемыми функциями
RU2017132978A (ru) Химерный рецептор антигена
JP2018518939A5 (es)
JP2020511136A5 (es)
HRP20220767T1 (hr) Liječenje raka uporabom humaniziranog kimernog receptora antigena anti-cd19
JP2020114264A5 (es)
IL263542B1 (en) Bispecific antibodies inhibit immunological checkpoint
Bottino et al. Cellular ligands of activating NK receptors
JP2020533958A5 (es)
JP2019523301A5 (es)
RU2017105160A (ru) Лечение рака с помощью химерного антигенного рецептора к cd33
JP2018525033A5 (es)
RU2014144143A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
RU2017108903A (ru) Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
RU2017133637A (ru) Иммуномодулирующие слитые белки и пути их применения
JP2020513754A5 (es)
JP2017519502A5 (es)
RU2017129591A (ru) МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК
JP2018527014A5 (es)
JP2018508219A5 (es)
JP2017513818A5 (es)